Login to Your Account

Clinic Roundup

Wednesday, August 10, 2011
Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, reported positive, topline data from its recently completed Phase II study of LX1032 (telotristat etiprate) in carcinoid syndrome. Five subjects receiving LX1032 achieved reductions of at least 30 percent in the number of bowel movements per day for two weeks or more; six reported adequate relief of symptoms; and nine had a complete biochemical response defined as a reduction of at least 50 percent in urinary 5-HIAA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription